Lymphoma / 2013 / Article / Fig 1

Research Article

Polo-Like Kinase 1: A Novel Target for the Treatment of Therapy-Resistant Mantle Cell Lymphoma

Figure 1

In vitro viability, proliferation, and apoptosis following PLK1 downregulation using BI2536/ASO. Figure 1 shows the changes to the level of viability, proliferation, and apoptosis in each of the therapy-resistant cell lines and parental GP following PLK1 downregulation with 48 and 72 hours treatment with either ASO ((a)–(c)) or BI2536 ((d)–(f)). In case of PLK1 ASO treatment, untreated/scrambled (SCR) ASO while in BI2536 treatment, vehicle- (DMSO-) treated cells were used as control groups for comparison in these experiments. (g) Represents the efficacy of BI2536 over ASO treatment in decreasing cell viability and increasing apoptosis in therapy-resistant and parental MCL cells. (h) MTT assay showing the restoration of the viability in therapy-resistant and parental MCL cells after PLK1 reintroduction by PLK1 ASO withdrawal (ASO-WD) for 48 and 96 hours following PLK1 silencing for 48 hours. SCR ASO (Con) was used as a control in this experiment. In these experiments, the values represent the means ± SE from triplicate wells of the 96-well plates. Similar results were obtained from two sets of independent experiments. indicates the statistical difference between control MCL cells and PLK1 downregulated MCL cells.
782903.fig.001a
(a)
782903.fig.001b
(b)
782903.fig.001c
(c)
782903.fig.001d
(d)
782903.fig.001e
(e)
782903.fig.001f
(f)
782903.fig.001g
(g)
782903.fig.001h
(h)

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.